Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)

6 Apr 2023

Abstract excerpt

Alternative lengthening of telomeres (ALT) supports telomere maintenance in 10-15% of cancers, thus representing a compelling target for therapy. By performing anti-cancer compound library screen on isogenic cell lines and using extrachromosomal telomeric C-circles, as a bona fide marker of ALT activity, we identify a receptor tyrosine kinase inhibitor ponatinib that deregulates ALT mechanisms, induces telomeric...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced biosensing and bioanalysis techniques
Share to CRISPR and Genetic Engineering
Share to Telomeres, Telomerase, and Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37024489
DOI: 10.1038/s41467-023-37633-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)PMID 37024489Read ↗

Human PC4 supports telomere stability and viability in cells utilizing the alternative lengthening of telomeres mechanismSemantic proximity Read ↗

TCGA Pan-Cancer Genomic Analysis of Alternative Lengthening of Telomeres (ALT) Related Genes.Semantic proximity Read ↗

Differential requirements for DNA repair proteins in immortalized cell lines using alternative lengthening of telomere mechanismsSemantic proximity Read ↗

Beyond ATRX: The heterogeneous basis of Alternative Lengthening of Telomeres in osteosarcoma.Semantic proximity Read ↗

Non-kinase targeting of oncogenic c-Jun N-terminal kinase (JNK) signaling: the future of clinically viable cancer treatmentsSemantic proximity Read ↗

Depletion of Ku70/80 reduces the levels of extrachromosomal telomeric circles and inhibits proliferation of ALT cellsSemantic proximity Read ↗

Detection of alternative lengthening of telomeres by telomere quantitative PCRSemantic proximity Read ↗

A C-circle assay for detection of alternative lengthening of telomere activity in FFPE tissueSemantic proximity Read ↗

Inhibition of p53 and/or AKT as a new therapeutic approach specifically targeting ALT cancersSemantic proximity Read ↗

Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).Semantic proximity Read ↗

Orphan nuclear receptors-induced ALT-associated PML bodies are targets for ALT inhibitionSemantic proximity Read ↗

The stress-induced lincRNA <i>JUNI</i> is a critical factor for cancer cell survival whose interactome is a prognostic signature in clear cell renal cell carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.